Portola announces the latest data on anticoagulant antidote andexanet June 26, 2015 Source: Medical Network Medical Network June 24th The field of blood diseases has been the focus of many biomedical companies. Among them, the development of anticoagulant drugs is a hot market for major biomedical giants. Currently in this field, Boehringer Ingelheim is proud of the latest Pradaxa. However, Eliquis jointly developed by Pfizer and Squibb and Xarelto under Bayer also occupy a large market share. However, with the widespread use of anticoagulant drugs, the resulting side effects of bleeding from patients have also surfaced. In view of this, many companies have begun research on anticoagulant antidote. Sprinkler irrigation and micro-irrigation automatic control equipment With the development of economy, water resources, energy shortage and labor cost increase, more and more water-saving irrigation systems will adopt automatic control. This article focuses on the advantages and classification of automated irrigation. Degree Irrigation Nozzle,Irrigation for Agriculture,Impact Drive Sprinkler,Plastic Drip Irrigation Fittings JIANGSU SKYPLAN GREENHOUSE TECHNOLOGY CO.,LTD , https://www.spgreenhouse.com
The advantages are as follows:
(1) It is possible to truly control the amount of irrigation, irrigation time and irrigation cycle in a timely and appropriate manner, thereby increasing crop yield and significantly improving water utilization.
(2) Saving labor and operating expenses.
(3) The work plan can be arranged conveniently and flexibly, and the management personnel do not have to go to the field at night or other inconvenient time.
(4) Since it can increase the effective working time every day, the initial capital investment in pipelines, pumping stations, etc. can be reduced accordingly.
classification:
First, fully automated irrigation system
The fully automated irrigation system does not require direct human involvement. The pre-programmed control procedures and certain parameters that reflect the water requirements of the crop can automatically open and close the pump for a long time and automatically irrigate in a certain order. The role of the person is simply to adjust the control program and overhaul the control equipment. In this system, in addition to emitters (heads, drip heads, etc.), pipes, fittings, pumps, and motors, it also includes central controllers, automatic valves, sensors (soil moisture sensors, temperature sensors, pressure sensors, water level sensors, and rain sensors). Etc.) and wires.
Second, semi-automatic irrigation system
In the semi-automated irrigation system, no sensors are installed in the field. The irrigation time, irrigation volume and irrigation period are controlled according to pre-programmed procedures, rather than feedback based on crop and soil moisture and meteorological conditions. The degree of automation of such systems is very different. For example, some pump stations implement automatic control, and some pump stations use manual control. Some central controllers are only one timer with simple programming function, and some systems have no central control. The controller, but only some of the sequential switching valves or volume valves are installed on each branch pipe.
Automated irrigation is the trend of the times. In the future water-saving irrigation projects, more and more automated irrigation systems will be applied.
Recently, Portola Pharmaceuticals of the United States announced the results of the latest clinical phase III study of its anticoagulant antidote andexanet alfa. The data disclosed here show that andexanet antagonizes the efficacy of Eliquis against anticoagulant by as much as 93.5%. In this clinical study with 23 participants, 80% of patients had a functional reversal of anti-coagulation factor Xa above the minimum level after using the drug. The amount of anticoagulant in the patient's plasma was significantly reduced, and the amount of thrombin produced by the patient also returned to normal levels. At the same time, the company also pointed out that the drug did not find significant side effects in the study.
Portola's andexanet has previously received FDA's breakthrough therapy certification. This drug is a chemical molecule that binds to factor Xa and antagonizes the anticoagulant function of such drugs by specific binding to factor Xa. The research data will further help the company promote the drug. Portola plans to apply for FDA approval for approval soon later this year.
Obviously, the imaginary enemy of andexanet is the similar product of the Boehringer Ingelheim idarucizumab. As an antidote to Pradaxa, the 5 mg dose of idarucizumab reverses the anticoagulant effect of Pradaxa within a few hours, and after 12 hours, the coagulation function of all patients will return to 90%. Currently idarucizumab is in the FDA's rapid approval channel.
Although Boehringer Ingelheim took the lead, who can laugh at the end is still unknown.